Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Double-Blind Placebo-Controlled 3-Way Cross-Over Study of GSK573719 in COPD
2009-014543-36Phase 2Completed
- Sponsor
- GSK
- Start
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of umeclidinium in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by GSK. Primary endpoint: Change from baseline in morning trough FEV1 at Day 15. Started Sep 2009; status: completed.
02
Drugs
umeclidinium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2009-014543-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014543-36.